Cost-utility analysis of an implantable cardioverterdefibrillator for the treatment of patients with ischemic or non-ischemic New York Heart Association class II or III heart failure in Colombia

• Published in: Biomedica : revista del Instituto Nacional de Salud Vol. 39; no. 3; pp. 502 - 512
• Main Authors: Atehortúa, Sara, Senior, Juan Manuel, Castro, Paula, Ceballos, Mateo, Saldarriaga, Clara, Giraldo, Nelson, Mora, Guillermo
• Format: Journal Article
• Language: English
• Published: Colombia Instituto Nacional de Salud 01.09.2019
• Subjects: Artículo Original; Colombia; Cost-Benefit Analysis; death, sudden, cardiac; Death, Sudden, Cardiac - prevention & control; Decision Trees; defibrillators; Defibrillators, Implantable - economics; Heart failure; Heart Failure - classification; Heart Failure - therapy; Humans; implantable; Meta-Analysis as Topic; Middle Aged; National Health Programs - economics; Quality of Life; Quality-Adjusted Life Years; Systematic Reviews as Topic; Time Factors; TROPICAL MEDICINE; Colombia; Heart failure; Colombia; implantable; death; sudden; cost-benefit analysis; defibrillators; cardiac; death, sudden, cardiac; desfibriladores; muerte súbita cardíaca; análisis costo-beneficio; insuficiencia cardíaca
• ISSN: 0120-4157; 2590-7379
• DOI: 10.7705/biomedica.4235

The use of an implantable cardioverter-defibrillator reduces the probability of sudden cardiac death in patients with heart failure. To determine the cost-utility relationship of an implantable cardioverter-defibrillator compared to optimal pharmacological therapy for patients with ischemic or non-ischemic New York Heart Association class II or III (NYHA II-III) heart failure in Colombia. We developed a Markov model including costs, effectiveness, and quality of life from the perspective of the Colombian health system. For the baseline case, we adopted a time horizon of 10 years and discount rates of 3% for costs and 3.5% for benefits. The transition probabilities were obtained from a systematic review of the literature. The outcome used was the quality-adjusted life years. We calculated the costs by consulting with the manufacturers of the device offered in the Colombian market and using national-level pricing manuals. We conducted probabilistic and deterministic sensitivity analyses. In the base case, the incremental cost-effectiveness ratio for the implantable cardioverter-defibrillator was USD$ 13,187 per quality-adjusted life year gained. For a willingness-to-pay equivalent to three times the gross domestic product per capita as a reference (USD$ 19,139 in 2017), the device would be a cost-effective strategy for the Colombian health system. However, the result may change according to the time horizon, the probability of death, and the price of the device. The use of an implantable cardioverter-defibrillator for preventing sudden cardiac death in patients with heart failure would be a cost-effective strategy for Colombia. The results should be examined considering the uncertainty.